PI Industries Ltd, a prominent player in the agrochemical sector, has witnessed an 11% decline in its shares over the past two trading days, raising concerns among investors. The primary cause of worry is the increased competition in the market for its essential product, pyroxasulfone, a crucial herbicide that contributes significantly to the company’s revenue and profits.
Challenges in the Pyroxasulfone Market
The recent approval granted to Chinese crop protection company Shandong Weifang Rainbow Chemicals to establish a manufacturing plant has intensified competition in the domestic pyroxasulfone market. PI Industries manufactures pyroxasulfone for Kumiai Chemicals, a Japan-based agrochemical company, and this product constitutes 35-40% of the company’s revenue.
Risks of Reliance on a Single Product
The heightened competition underscores the risks associated with a heavy reliance on a single product and the potential for margin erosion. PI Industries’ custom synthesis manufacturing (CSM) business, which includes pyroxasulfone, is export-oriented. Despite management assurances of well-diversified export growth, investors must be aware of the impact on earnings due to potential price erosion.
Kumiai’s Role and Patent Protection
Despite the competitive landscape, Nuvama Institutional Equities suggests that the entry of Shandong Weifang Rainbow Chemicals will be gradual. Kumiai, the primary recipient of pyroxasulfone from PI Industries, has patent protection for multiple combinations and maintains brand leadership in key markets such as the US. This positioning could mitigate the immediate threat of price erosion.
Analyst Perspective and Future Outlook
Analyst Prathamesh Sawant from Axis Securities emphasizes PI Industries’ strong track record, citing a 10-year revenue CAGR of 19% and PAT CAGR of 29%. The company’s FY24 guidance of 18-20% revenue growth and improvements in margin and returns provides some reassurance amid the current challenges.
Sawant highlights the growth potential in other segments, such as speciality chemicals, pharmaceuticals, and the domestic business. Investors will closely monitor the acquisition of pharma businesses and brand launches in the domestic market. Additionally, the impact of El Nino on Indian agriculture could influence demand for PI Industries’ products.
Valuation and Investor Perception
Despite the recent share price decline, PI Industries’ valuations appear reasonable, trading at 27x FY25 estimated earnings, which discounts historical valuations. Investors will continue to assess the company’s performance and strategic moves in navigating the evolving market dynamics.
Summary
PI Industries faces a challenging period with increased competition in the pyroxasulfone market, emphasizing the importance of diversification and strategic growth in other business segments. The company’s ability to navigate these challenges, capitalize on acquisitions, and adapt to market shifts will be crucial in shaping its future performance. Investors will keenly observe management actions and market developments in the coming months.
Disclaimer: We do not endorse or encourage you to take trades or investment decisions based upon our posts/research, all of your trading and investment activities are your own and should be taken through consultation with reputed financial advisors. The analysis posted on this website has been created by involving multiple mediums which are present over the Internet.